Assay testing, performed by the supplier prior to release of bupivacaine was within specification.Review of the sterilization certificate for the tray revealed that the product was processed according to validated specification requirements and parameters.Supplied drug components stability post ethylene oxide sterilization are periodically monitored throughout their expiry.Our records show that the supplied drug components continue to meet potency specifications.Complaint information review found no trends relevant to the drug lot number, reported in this complaint.The anesthetics are supplied items and the complaint notification was forwarded to the supplier.Based on available information and evidences no product quality problem could be confirmed.Possible causes of lack of effect may be administration technique or patient anatomical variations, including pathological or psychological factors.Review of device history records and incoming records found no discrepancies or anomalies relevant to the complaint.Catalog and udi unknown, 510k unknown.This remediation mdr was generated under protocol (b)(4), as a result of warning letter cms# (b)(4).
|